Employees: 142
Size Sana Biotechnology (SANA) is a United States Health Care company (Biotechnology) with a market value of $554M, the 2597th largest of 3,085 United States companies the cockpit tracks. Shares closed at $1.85 on 18 Nov 2026.
Performance Over six months the shares fell 40.5%, against -13.8% for the median peer and -2.2% for the United States market (cap-weighted) — 4th lowest of 19 in its peer set.
Capital Return on invested capital runs 143.9 points below its cost of capital (15.6% WACC).
Short interest Short interest is 13.6% of the free float (30 Oct 2026).
Next results Next results expected around 23 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$10.6M | -$12.8M | -$15.5M | -$30.9M | -$27.7M |
| EBITDA | -$166M | -$178M | -$256M | -$295M | -$241M |
| Net income | -$149M | -$244M | -$267M | -$283M | -$269M |
| Free cash flow | -$145M | -$145M | -$257M | -$274M | -$311M |
| Capital expenditure | $3.57M | $938,000 | $33.4M | $20.0M | $20.9M |
| Total debt | $53.8M | $78.9M | $94.2M | $104M | $108M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SANA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -21.6% | -14.3% | 4th lowest of 21 |
| 6-month return | -40.5% | -13.8% | 4th lowest of 19 |
| Distance from 52-week high | -66.3% | -45.5% | 4th lowest of 21 |
| ROIC minus cost of capital | -143.9 pp | -3.4 pp | lowest of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Sana Biotechnology SANA | United States | $554M | -41% | n/a | n/a | n/a | n/a | n/a |
| Hvsen Biotechnology 300871.SZ | China | $553M | -22% | +2% | 17% | 2.3× | n/a | n/a |
| Boji Medical Technology 300404.SZ | China | $561M | -6% | +32% | 4% | 3.4× | 31.9% | +27.2% |
| Wave Life Sciences WVE | United States | $546M | -55% | -35% | -321% | 2.2× | n/a | n/a |
| Climb Bio CLYM | United States | $546M | -12% | n/a | n/a | n/a | n/a | n/a |
| Frontage 1521.HK | Hong Kong | $542M | +113% | +10% | 8% | 2.3× | 14.3% | +15.4% |
| Genfit GNFT.PA | France | $571M | +22% | +28% | -130% | 11.0× | 39.8% | +143.5% |
| Ascletis Pharma 1672.HK | Hong Kong | $571M | -72% | -59% | -71,976% | 1,794.8× | n/a | n/a |
| 4D Molecular Therapeutics FDMT | United States | $578M | +23% | +79,952% | -226% | 3.2× | n/a | n/a |
| Beijing Bohui Innovation Biotechnology 300318.SZ | China | $518M | -20% | -1% | -13% | 6.2× | n/a | n/a |
| Alebund Pharmaceuticals (Jiangsu) 9637.HK | Hong Kong | $595M | n/a | +674% | -495% | 26.8× | n/a | n/a |
| LongBio Pharma (Suzhou) 1779.HK | Hong Kong | $510M | n/a | n/a | n/a | n/a | n/a | n/a |
| Anhui Huaheng Biotechnology 688639.SS | China | $605M | -45% | +7% | 3% | 1.9× | n/a | n/a |
| Surrozen SRZN | United States | $605M | +17% | +192% | -485% | 48.5× | n/a | n/a |
| Valneva VLA.PA | France | $508M | -6% | -27% | -87% | 3.9× | n/a | n/a |
| Design Therapeutics DSGN | United States | $606M | -15% | n/a | n/a | n/a | n/a | n/a |
| Beijing Scitop Bio-Tech 300858.SZ | China | $501M | -28% | +4% | 8% | 7.5× | n/a | n/a |
| Sinotherapeutics 688247.SS | China | $494M | -19% | -17% | 0% | 6.2× | 29.4% | +7.0% |
| Getein Biotech 603387.SS | China | $625M | -13% | +8% | 21% | 2.6× | -8.9% | -1.3% |
| Liaoning Dingjide Petrochemical 603255.SS | China | $490M | -24% | +70% | 5% | 5.2× | n/a | n/a |
| CHO Pharma 6586.TWO | Taiwan | $488M | +24% | -47% | -17,694% | 8,281.1× | n/a | n/a |